Cassava Sciences (SAVA) falls to a new 52-week low. A CUNY report shows “egregious misconduct” in SAVA’s research. The report highlights that they found questionable data management and record keeping. Twenty of the research papers in question provided “key support” for Simufilam, the company’s Alzheimer’s drug. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.